Nebivolol Actavis (Nebivolol Hydrochloride)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractile force, leading to lower blood pressure. In addition, it stimulates endothelial nitric‑oxide production, causing vasodilation that further contributes to its antihypertensive effect without significant β2‑receptor blockade.

The appropriate dose of Nebivolol Actavis is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any concomitant medications. Physicians typically start with a low dose and may adjust it to achieve target blood pressure or heart‑failure goals, following local prescribing guidelines.

Safety data for Nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements if applicable), and necessary import documentation.

Nebivolol is distinguished by its β1‑selectivity combined with nitric‑oxide‑mediated vasodilation, which can result in fewer metabolic side effects and better tolerability compared with non‑selective beta‑blockers. It may be preferred in patients who require blood‑pressure control without significant bronchospasm risk, though individual response and comorbidities guide final selection.

Nebivolol should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Nebivolol is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule prescribed by their healthcare professional to maintain consistent blood‑pressure control.

Serious adverse events include severe bradycardia, heart block, bronchospasm in patients with reactive airway disease, and rare cases of hepatic dysfunction or allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or signs of an allergic reaction.

Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and those in cardiogenic shock. Caution is also advised for individuals with uncontrolled asthma, severe hepatic impairment, or who are pregnant without clear benefit.